2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…2019 American Transplant Congress
Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation
*Purpose: The aim of this study was to determine whether intraoperative autologous transfusion in liver transplant patients with HCC affects the rate of recurrence.*Methods: We…2019 American Transplant Congress
DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist
*Purpose: Currently, adult HCC patients are prioritized for liver transplantation by receiving MELD exception points, determined primarily by time on waitlist without regard to actual…2019 American Transplant Congress
Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…2019 American Transplant Congress
Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
*Purpose: Although liver transplantation (LT) is a preferred treatment for selected patients with Hepatocellular carcinoma (HCC), HCC-recurrence would be a still important medical problem. Most…2019 American Transplant Congress
Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation
Severance hospital, Seoul, Korea, Republic of
*Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The…2019 American Transplant Congress
Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation
*Purpose: Recent studies from United Network of Organ Sharing (UNOS) Region 5 reported excellent outcomes after liver transplantation (LT) after successful down-staging in HCC patients…2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…2019 American Transplant Congress
Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma
1Columbia University Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than…2019 American Transplant Congress
Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time
1Tampa General Hospital, Tampa, FL, 2University of South Florida, Tampa, FL
*Purpose: The purpose of this study was to determine any difference in resource utilization since the implementation of the mandatory six month wait-time policy for…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 23
- Next Page »